Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nipro ( (JP:8086) ) has shared an update.
Nipro reported consolidated results for the nine months ended Dec. 31, 2025, with net sales edging up 1.7% year-on-year to ¥487.3 billion, while operating profit jumped 20.5% to ¥26.7 billion and profit attributable to owners of parent surged 153% to ¥16.7 billion. The company’s equity-to-asset ratio remained around 21%, and it maintained its full-year forecast, projecting ¥677 billion in sales and a 39.1% rise in operating profit, while planning a total annual dividend of ¥28 per share for the fiscal year ending March 31, 2026.
Results were supported in part by changes in the consolidation scope, with seven companies newly included and one excluded, though Nipro reported no changes in accounting policies or estimates. Earnings per share improved markedly, with basic EPS for the nine-month period rising to ¥102.30 from ¥40.43 a year earlier, underscoring a strong recovery in profitability that may bolster investor confidence and reinforce the group’s financial base heading into the final quarter.
The most recent analyst rating on (JP:8086) stock is a Hold with a Yen1593.00 price target. To see the full list of analyst forecasts on Nipro stock, see the JP:8086 Stock Forecast page.
More about Nipro
Nipro Corporation is a Japan-based medical device and pharmaceutical company listed on the Tokyo Stock Exchange. It develops and manufactures products such as dialysis equipment and other healthcare-related devices, serving hospitals and medical markets in Japan and internationally.
YTD Price Performance: -2.20%
Average Trading Volume: 488,769
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen235.6B
For detailed information about 8086 stock, go to TipRanks’ Stock Analysis page.